Lupin Share Price Outlook: Citi Downgrade Signals Margin Pressure And US Sales Slowdown
Key Takeaways
- Citi's note projects US base sales around $975 million by FY29 and margin compression to about 20%.
- Lupin stock has fallen about 10% in the last month; RSI 29.3 and bearish trend below eight SMAs.
- Apixaban could provide near-term earnings support in FY28, but sustainability is uncertain.
- The Lupin price target is referenced but the exact figure is not disclosed in the source.
With around 201,000 monthly searches for Lupin Share Price, retail investors are actively scanning Lupin's trajectory as Citi flags potential headwinds in the US base business and margin pressure. The Citi note pegs US base sales at around $975 million by FY29, and suggests margins could fall to roughly 20% from nearly 30% today. This combination could compress Lupin earnings growth unless new high-margin products offset the decline. The market has responded: Lupin stock has dropped roughly 10% in the last month, while the 14-day RSI sits at 29.3, and the stock remains below all eight key SMAs, signaling a bearish tone for now.
Lupin Share Price Under Pressure: Citi Downgrade Signals US Sales And Margin Headwinds
According to Citi's note, Lupin's US base business is expected to lose momentum, with US base sales projected to be around $975 million by FY29. Margins could compress to about 20% from the current level near 30%, which would weigh on earnings growth unless new high-margin products offset the decline. The note also suggests Apixaban could provide some earnings support in FY28, but this benefit may be short-lived and insufficient to sustain long-term growth. The note further lowers FY27 earnings per share by 14% and underscores risk from weaker US momentum and limited sustainability of upcoming product benefits.
In addition to the US dynamics, investors should note that Lupin's market capitalization stands at Rs 98,497 crore and the 52-week high is Rs 2,529.50. The stock is currently trading below the eight key SMAs, and the 14-day RSI is 29.3, underscoring a bearish technical setup that could persist until new catalysts appear.
Lupin Earnings Outlook: EPS Cut And Margin Contraction
The earnings trajectory is shaped by a 14% cut to FY27 EPS, and a potential margin compression to around 20% from near 30%, unless Apixaban and other high-margin products offset the decline. Apixaban's contribution in FY28 may help earnings in the near term, but the risk remains that this benefit is not sustainable over the longer horizon. The overall tone suggests the risk-reward has shifted toward downside unless Lupin can accelerate growth in the US and other geographies.
Lupin Stock Technicals: RSI And Moving Averages Show Bearish Momentum
Technically, Lupin is trading below all eight key SMAs, pointing to a broad-based downward trend. The 14-day RSI at 29.3 indicates oversold conditions, which can imply a short-term bounce if buying interest returns. However, RSI alone does not guarantee reversals, and the current trend suggests investors should wait for sustained buying signals before taking fresh positions.
Lupin Price Target And Valuation Signals: What Citi's Note Implies
In the context of Lupin's valuation, Citi's note references a Lupin price target but does not disclose the exact figure. Investors should treat this as a directional view rather than a precise forecast, and should consider the underlying risks along with the price target framing when evaluating entry or exit points. The stock's current market context includes a market capitalization of Rs 98,497 crore and a 52-week high of Rs 2,529.50, providing a sense of the potential downside and upside versus the historical peak.
For deeper data-driven insights, consider Swastika's Swastika's Sarthi AI stock assistant.
Related Reads
- Lupin Share Price: Q1 Earnings Beat And Margin Expansion Explained
- Sun Pharma Share Price And US Tariff Talks: What Indian Retail Investors Must Watch
- Sun Pharma Share Price And The US Tariff Debate: What Indian Retail Investors Must Know
Frequently Asked Questions
What are the key risks highlighted by the Citi note for Lupin's US base business?
Citi projects a slowdown in Lupin's US base business, with US sales seen at around $975 million by FY29, and margins possibly compressing from around 30% to about 20% if gains from new products don't offset the decline.
How could Apixaban affect Lupin's earnings according to Citi's note?
Apixaban is expected to contribute to US earnings in FY28, but Citi views this as potentially short-lived and not enough to sustain long-term earnings growth.
What is Lupin's recent share price momentum and technical setup?
Lupin shares have declined about 10% over the past month, with the 14-day RSI at 29.3, and the stock trading below all eight key SMAs, indicating bearish momentum despite oversold conditions.
What does the earnings outlook look like after Citi's FY27 EPS cut?
Citi cut FY27 earnings per share by 14% and warned that weaker US momentum and margin compression could limit sustained earnings growth unless new high-margin products offset the declines.
Is there a Lupin price target mentioned, and how should investors interpret it?
The note references a Lupin price target but does not disclose the exact figure. Investors should treat this as a directional view rather than a precise forecast and consider the underlying risks.
Conclusion
This article was published without a generated conclusion. Please review and add a conclusion before publishing.
Open your trading and demat account here
Reference :
1 : Economictimes
